[The value of xamoterol in moderate ischemic cardiac insufficiency].
Xamoterol is a partial beta-1 adrenergic agonist capable of stabilising the beta-1 receptor to 43% of their maximal activity. Xamoterol was administered to 10 patients with moderate ischaemic heart failure at an oral dose of 200 mg twice a day. After 3 months, there was an improvement in left ventricular function: 28% reduction in the end-diastolic pressure (p less than 0.01), 12% reduction in ventricular volume (p less than 0.05) with a marked increase in the inotropic state. The exercise tolerance was also increased (+ 30 watt; p less than 0.05) and several indices suggest an improvement in myocardial metabolism. In conclusion, xamoterol is a positive inotrope which does not present the phenomenon of tachyphylaxis during the prolonged administration.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy*; D004341:Drug Evaluation; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D005082:Physical Exertion / Q000187:drug effects; D011412:Propanolamines / Q000627:therapeutic use*; D017307:Xamoterol
D000318:Adrenergic beta-Agonists; D011412:Propanolamines; D017307:Xamoterol; D007545:Isoproterenol
Intérêt du xamotérol dans l'insuffisance cardiaque modérée d'étiologie ischémique.